BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study
BOS172738 showed preliminary efficacy and a manageable safety profile in RET-altered tumors, including those resistant to prior therapies and in patients with brain metastases.
Authors
- Brenda I. Jeglinski
- Paul Gougis (ORCID: https://orcid.org/0000-0003-3064-7043)
- Patrick Schöffski (ORCID: https://orcid.org/0000-0001-5980-030X)
- Herbert H. Loong (ORCID: https://orcid.org/0000-0002-6607-1106)
- Mitchell Keegan (ORCID: https://orcid.org/0009-0001-0186-9002)
- Jin‐Yuan Shih (ORCID: https://orcid.org/0000-0002-2854-5067)
- José Trigo (ORCID: https://orcid.org/0000-0002-4489-2683)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- B. Doger
- A. Gazzah
- V. Subbiah
- K. Andreas
- Antoine Italiano
Institutions
- Université de Bordeaux (FR)
- Inserm (FR)
- Chinese University of Hong Kong (HK)
- Yonsei University (KR)
- Université Paris Cité (FR)
- Institut Gustave Roussy (FR)
- Sorbonne Université (FR)
- AVEO Oncology (United States) (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Sarah Cannon (US)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- National Taiwan University Hospital (TW)
- Institut Bergonié (FR)
- Gangnam Severance Hospital (KR)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- KU Leuven (BE)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105543
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00